Research Article
The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan
Table 1
Baseline characteristics of breast cancer patients according to different neoadjuvant chemotherapeutic regimens.
| | Characteristics | Epirubicin (n = 183) | PLD (n = 183) | Total (n = 366) | value | | N | (%) | n | (%) | n | (%) |
| | Clinical stage f | | | | | | | 1.000 | | IA | 12 | (6.6) | 12 | (6.6) | 24 | (6.6) | | | IIA | 63 | (34.4) | 63 | (34.4) | 126 | (34.4) | | | IIB | 78 | (42.6) | 78 | (42.6) | 156 | (42.6) | | | IIIA | 23 | (12.6) | 23 | (12.6) | 46 | (12.6) | | | IIIB | 6 | (3.3) | 6 | (3.3) | 12 | (3.3) | | | IIIC | 1 | (0.5) | 1 | (0.5) | 2 | (0.5) | | | Molecular subtype | | | | | | | 1.000 | | Luminal type (Her2 negative) | 85 | (46.4) | 85 | (46.4) | 170 | (46.4) | | | Her2 positive | 65 | (35.5) | 65 | (35.5) | 130 | (35.5) | | | TNBC | 33 | (18.0) | 33 | (18.0) | 66 | (18.0) | | | Chemoregimen with taxane before surgery | 142 | (77.6) | 142 | (77.6) | 284 | (77.6) | 1.000 | | Histological grade | | | | | | | 1.000 | | Grade 1-2 (well/moderately differentiated) | 107 | (58.5) | 107 | (58.5) | 214 | (58.5) | | | Grade 3 (poorly differentiated) | 69 | (37.7) | 69 | (37.7) | 138 | (37.7) | | | Grade 9 (unknown) | 7 | (3.8) | 7 | (3.8) | 14 | (3.8) | | | Age (mean ± SD)# | 49.3 | ±9.7 | 49.7 | ±8.6 | 49.5 | ±9.2 | 0.789 | | Tumor size (mm) (mean ± SD)# | 35.6 | ±19.5 | 34.8 | ±21.8 | 35.2 | ±20.6 | 0.239 | | Surgery | | | | | | | 0.090 | | Partial mastectomy | 85 | (46.4) | 68 | (37.2) | 153 | (41.8) | | | Total mastectomy | 98 | (53.6) | 115 | (62.8) | 213 | (58.2 | | | Therapy | | | | | | | | | Radiotherapy (RT) | 133 | (72.7) | 138 | (75.4) | 271 | (74.0) | 0.633 | | Hormone therapy (HT) | 132 | (72.1) | 126 | (68.9) | 258 | (70.5) | 0.567 | | Target therapy (TT) | 70 | (38.3) | 70 | (38.3) | 140 | (38.3) | 1.000 | | Recurrence | 20 | (10.9) | 16 | (8.7) | 36 | (9.8) | 0.598 | | Died | 14 | (7.7) | 25 | (13.7) | 39 | (10.7) | 0.090 | | Pathologic complete response (pCR) | 36 | (19.7) | 33 | (18.0) | 69 | (18.9) | 0.789 |
|
|
Chi-square test. fFisher’s exact test. #Mann–Whitney U test.
|
